ArticleInfection and immunity2002
Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Advances in cryptococcal infections-associated immunopathology and potential therapeutic strategies.Frontiers in pharmacology · 2026Review
- Fungal mechanisms of intracellular survival: what can we learn from bacterial pathogens?Infection and immunity · 2023Review
- Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis.Open forum infectious diseases · 2023Article
- Fungal extracellular vesicle-mediated regulation: from virulence factor to clinical application.Frontiers in microbiology · 2023Review
- Contact-dependent inhibition of HIV-1 replication inCell reports. Medicine · 2021Article
- Resistance and Tolerance to Cryptococcal Infection: An Intricate Balance That Controls the Development of Disease.Frontiers in immunology · 2019Review
- The VraSR regulatory system contributes to virulence in Streptococcus suis via resistance to innate immune defenses.Virulence · 2018Article
- Article
- Fungal Strategies to Evade the Host Immune Recognition.Journal of fungi (Basel, Switzerland) · 2017Review
- Autophagy and Reactive Oxygen Species Are Involved in Neutrophil Extracellular Traps Release Induced by C. albicans Morphotypes.Frontiers in microbiology · 2016Article
- Real-Time Imaging of Interactions of Neutrophils with Cryptococcus neoformans Demonstrates a Crucial Role of Complement C5a-C5aR Signaling.Infection and immunity · 2016Article
- Capsular polysaccharides from Cryptococcus neoformans modulate production of neutrophil extracellular traps (NETs) by human neutrophils.Scientific reports · 2015Article
- Capsular Material of Cryptococcus neoformans: Virulence and Much More.Mycopathologia · 2012Article
- Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo.Cellular microbiology · 2010Article
- Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions.Infection and immunity · 2010Article
- Complement and neutrophil function changes after liver resection in humans.World journal of surgery · 2009Article
- The capsule of the fungal pathogen Cryptococcus neoformans.Advances in applied microbiology · 2009Review
- Glycoconjugates and polysaccharides of fungal cell wall and activation of immune system.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2008Article
- Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis.Infection and immunity · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Cryptococcus neoformans and cryptococcal surface polysaccharides influenced C5aR expression on human polymorphonuclear neutrophils (PMN). Encapsulated and acapsular strains produced dramatically different effects. Treatment of PMN with acapsular cryptococci up-regulated C5aR expression; whereas treatment with encapsulated cells suppressed C5aR expression. Glucuronoxylomannan (GXM), the principal constituent of the cryptococcal capsule, was responsible for such inhibition. Increased C5aR expression following treatment with acapsular cryptococci was accompanied by increased binding of C5a to PMN, increased superoxide production in response to stimulation with C5a, and an increased chemotactic response to C5a. Conversely, decreased C5aR expression following treatment with encapsulated cryptococci or acapsular cryptococci that had been pretreated with GXM was accompanied by decreased binding of C5a to PMN and a decreased chemotactic response to C5a. Our results raise the possibility that the down-regulation of C5aR expression by encapsulated cryptococci might alter PMN function at the site of cryptococcal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.